[siteorigin_widget class=”SiteOrigin_Widget_Image_Widget”][/siteorigin_widget]

Civica Rx recently welcomed the local community for the official opening of its new headquarters in Lehi, UT, just outside of Salt Lake City.

Joining the Civica team as speakers for the opening ceremony and ribbon cutting were Utah Governor, Gary Herbert; U.S. Congressman Ben McAdams (UT); Intermountain Healthcare CEO, Marc Harrison, MD; University of Utah Senior Director Drug Information Services, Erin Fox; and Civica Rx Chairman of the Board and the “brainchild” of the Civica concept, Dan Liljenquist, who is also SVP of Strategy at Intermountain Healthcare. U.S. Senators Mitt Romney and Mike Lee of Utah provided congratulatory video remarks.


“Together we celebrate the reason why Civica exists, in purpose and in brick and mortar, and that is to do what is in the best interest of patients by stabilizing the supply of generic medications,” said Martin VanTrieste, Civica CEO. “Drug shortages strain hospital staff, lead to delayed surgeries and sub-optimal treatments for patients, and can lead to unpredictable price increases that result in budgetary instability in hospitals.”

As reported in one of the local Utah media outlets in attendance, event speakers highlighted the challenges associated with generic drug shortages in the nation’s hospitals, shared enthusiasm about the promise of Civica as an innovative, collaborative approach to stabilizing generic drug supply, and expressed pride in welcoming Civica to Utah. Dan Liljenquist, Civica Board Chair and SVP at Intermountain Healthcare, also shared the origins of the Civica concept about three years ago.

Civica exists in the public interest as a non-profit, non-stock corporation focused on reducing chronic generic drug shortages, which have negatively impacted patient care for over a decade. It was founded by leading US hospital systems concerned about drug shortages and philanthropic organizations passionate about improving healthcare and is led by a team with vast hospital operations and biopharmaceutical manufacturing experience.


Leave a Reply

Your email address will not be published. Required fields are marked *